EIF2AK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL317189	0.43	6/20
SCHEMBL317371	0.43	5/20
SCHEMBL317793	0.50	3/20
SCHEMBL580579	0.48	3/20
SCHEMBL317203	0.47	3/20
SCHEMBL170980	1.00	2/20
SCHEMBL460367	0.47	2/20
SCHEMBL91478	0.47	2/20
SCHEMBL413527	0.47	2/20
SCHEMBL394705	0.46	2/20
SCHEMBL91582	0.44	2/20
SCHEMBL146981	0.43	2/20
SCHEMBL317159	0.40	2/20
SCHEMBL396747	0.40	2/20
SCHEMBL317746	0.39	2/20
Erlotinib (SCHEMBL8413)	1.00	1/20
Pelitinib (SCHEMBL93756)	1.00	1/20
Pelitinib (SCHEMBL93757)	1.00	1/20
Axitinib (SCHEMBL172918)	1.00	1/20
Gsk-690693 (SCHEMBL310452)	1.00	1/20

Clinical trials — most relevant to EIF2AK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short Course of Interferon Treatment in Patients With HCV Infection	PHASE4	COMPLETED
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients	PHASE2/PHASE3	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer	PHASE2	RECRUITING
IdB 1016 Treatment for Hepatitis C Disease	PHASE1/PHASE2	COMPLETED
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C	PHASE2	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Hepatitis C in Clinically Discordant Hemophilic Siblings	nan	COMPLETED
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile	nan	UNKNOWN
Viral and Epigenetic Influences in CRSwNP	nan	ACTIVE_NOT_RECRUITING
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
GADD34 and Type I IFN Response Genes in SLE	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis	nan	COMPLETED
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults	nan	COMPLETED
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies	nan	COMPLETED
Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A	nan	COMPLETED
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
Myeloid Cells in Patients With Covid-19 Pneumonia	nan	UNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF2AK2 binder may also engage these)

Protein	Name	Similarity
Q03963	—	0.999	Q03963 →
Q63184	—	0.996	Q63184 →
P52332	—	0.992	P52332 →
Q76II0	—	0.989	Q76II0 →
Q28317	—	0.989	Q28317 →
Q9VEZ5	—	0.989	Q9VEZ5 →
Q4R8E0	—	0.989	Q4R8E0 →
Q09488	—	0.988	Q09488 →
Q2HWD6	—	0.988	Q2HWD6 →
Q28889	—	0.988	Q28889 →
Q0VD22	—	0.988	Q0VD22 →
Q91909	—	0.988	Q91909 →
Q9H0M0	—	0.988	Q9H0M0 →
Q9LT35	—	0.987	Q9LT35 →
Q9SF12	—	0.987	Q9SF12 →
Q6YY75	—	0.987	Q6YY75 →
F4IJK6	—	0.987	F4IJK6 →
Q9JLM8	—	0.987	Q9JLM8 →
Q78EA7	—	0.987	Q78EA7 →
P32865	—	0.987	P32865 →
Q9TYU5	—	0.987	Q9TYU5 →
O80396	—	0.987	O80396 →
Q66I46	—	0.987	Q66I46 →
Q9SKC3	—	0.987	Q9SKC3 →
Q5MPA9	—	0.986	Q5MPA9 →
P25799	—	0.986	P25799 →
STK33	Serine/threonine-protein kinase 33	0.986	landscape →
A6ZL17	—	0.986	A6ZL17 →
O19064	—	0.986	O19064 →
P04157	—	0.986	P04157 →